DALLAS, May 24 /PRNewswire/ -- HEMOBIOTECH, INC. announced today that the Company registration on form SB-2 was declared effective by the Securities and Exchange Commission on Friday, May 13, 2005.
“This is a major development for HEMOBIOTECH,” said Dr. Arthur P. Bollon, Chairman and Chief Executive Officer of the Company. “The registration follows our private placement raising $4.5 million in October 2004.”
About HEMOBIOTECH
HEMOBIOTECH is a biopharmaceutical company developing HemoTech, which is a chemically modified hemoglobin being developed as a substitute for human blood.
For more information about HEMOBIOTECH visit the web site at http://www.hemobiotech.com/ , or contact:
Arthur P. Bollon, Ph.D. Chairman & Chief Executive Officer HEMOBIOTECH, INC. J.P. Morgan International Plaza 14221 Dallas Parkway, Suite 1500 Dallas, Texas 75254 214-540-8411 214-540-8416 fax
HEMOBIOTECH, INC.
CONTACT: Arthur P. Bollon, Ph.D., Chairman & Chief Executive Officer ofHEMOBIOTECH, INC., +1-214-540-8411, or fax, +1-214-540-8416
Web site: http://www.hemobiotech.com/